File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Clinical and hemodynamic outcomes in patients with chronic venous insufficiency after oral micronized flavonoid therapy

TitleClinical and hemodynamic outcomes in patients with chronic venous insufficiency after oral micronized flavonoid therapy
Authors
Issue Date2001
PublisherSage Publications, Inc. The Journal's web site is located at http://ves.sagepub.com
Citation
Vascular Surgery, 2001, v. 35 n. 6, p. 443-447 How to Cite?
AbstractThe aim of this study was to prospectively investigate the clinical efficacy of Daflon therapy in patients with mild to moderate chronic venous insufficiency (CVI) (clinical class 1-4) and to assess the changes in venous hemodynamics by using air plethysmography (APG). Fifty-six limbs in 28 patients were studied. They all had primary venous insufficiency with no venous obstruction, and mixed deep and superficial venous incompetence was found in 64% of the limbs. There was a significant decrease in symptom score for swelling and heaviness after 6 months of Daflon therapy. The symptom score for cramps also showed improvement though it did not reach statistical significance. Pain was significantly reduced with a mean pain score of 21.8 ±19.3% before comparing to 10.4 ±20.2% after 6 months of Daflon therapy (p < 0.01). This was also associated with a decrease in mean calf circumference from 37.0 ±4.3 to 36.4 ±4.3 cm (p < 0.001). There was no significant change in the venous filling index (VFI), ejection fraction (EF), and residual volume fraction (RVF) before and after 6 months of Daflon therapy (VFI: 3.7 ±3.5 vs 3.4 ±2.5 mL/s, EF: 54.5 ±15.9% vs 57.7 ±19.7%, RVF: 41.4 ±19.2% vs 39.4 ±24.2%). The clinical improvement without associated changes in venous hemodynamics as measured by APG suggests that Daflon mainly works by modifying the microcirculatory environment not detected by APG and this microcirculatory change is associated with clinical improvement. In this regard, Daflon would be especially useful for symptomatic relief in patients with functional venous insufficiency who do not have clinical evidence of varicose veins but suffer from symptoms of venous insufficiency.
Persistent Identifierhttp://hdl.handle.net/10722/84184
ISSN
1999 Impact Factor: 0.158
References

 

DC FieldValueLanguage
dc.contributor.authorTing, ACWen_HK
dc.contributor.authorCheng, SWKen_HK
dc.contributor.authorWu, LLHen_HK
dc.contributor.authorCheung, GCYen_HK
dc.date.accessioned2010-09-06T08:49:57Z-
dc.date.available2010-09-06T08:49:57Z-
dc.date.issued2001en_HK
dc.identifier.citationVascular Surgery, 2001, v. 35 n. 6, p. 443-447en_HK
dc.identifier.issn0042-2835en_HK
dc.identifier.urihttp://hdl.handle.net/10722/84184-
dc.description.abstractThe aim of this study was to prospectively investigate the clinical efficacy of Daflon therapy in patients with mild to moderate chronic venous insufficiency (CVI) (clinical class 1-4) and to assess the changes in venous hemodynamics by using air plethysmography (APG). Fifty-six limbs in 28 patients were studied. They all had primary venous insufficiency with no venous obstruction, and mixed deep and superficial venous incompetence was found in 64% of the limbs. There was a significant decrease in symptom score for swelling and heaviness after 6 months of Daflon therapy. The symptom score for cramps also showed improvement though it did not reach statistical significance. Pain was significantly reduced with a mean pain score of 21.8 ±19.3% before comparing to 10.4 ±20.2% after 6 months of Daflon therapy (p < 0.01). This was also associated with a decrease in mean calf circumference from 37.0 ±4.3 to 36.4 ±4.3 cm (p < 0.001). There was no significant change in the venous filling index (VFI), ejection fraction (EF), and residual volume fraction (RVF) before and after 6 months of Daflon therapy (VFI: 3.7 ±3.5 vs 3.4 ±2.5 mL/s, EF: 54.5 ±15.9% vs 57.7 ±19.7%, RVF: 41.4 ±19.2% vs 39.4 ±24.2%). The clinical improvement without associated changes in venous hemodynamics as measured by APG suggests that Daflon mainly works by modifying the microcirculatory environment not detected by APG and this microcirculatory change is associated with clinical improvement. In this regard, Daflon would be especially useful for symptomatic relief in patients with functional venous insufficiency who do not have clinical evidence of varicose veins but suffer from symptoms of venous insufficiency.en_HK
dc.languageengen_HK
dc.publisherSage Publications, Inc. The Journal's web site is located at http://ves.sagepub.comen_HK
dc.relation.ispartofVascular Surgeryen_HK
dc.rightsJournal of Vascular Surgery. Copyright © Mosby, Inc.en_HK
dc.titleClinical and hemodynamic outcomes in patients with chronic venous insufficiency after oral micronized flavonoid therapyen_HK
dc.typeArticleen_HK
dc.identifier.openurlhttp://library.hku.hk:4550/resserv?sid=HKU:IR&issn=0741-5214&volume=35&spage=443&epage=447&date=2001&atitle=Clinical+and+hemodynamic+outcomes+in+patients+with+chronic+venous+insufficiency+after+oral+micronized+flavonoid+therapyen_HK
dc.identifier.emailCheng, SWK: wkcheng@hkucc.hku.hken_HK
dc.identifier.authorityCheng, SWK=rp00374en_HK
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.pmid16222383-
dc.identifier.scopuseid_2-s2.0-0035174899en_HK
dc.identifier.hkuros89110en_HK
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-0035174899&selection=ref&src=s&origin=recordpageen_HK
dc.identifier.volume35en_HK
dc.identifier.issue6en_HK
dc.identifier.spage443en_HK
dc.identifier.epage447en_HK
dc.publisher.placeUnited Statesen_HK
dc.identifier.scopusauthoridTing, ACW=7102858552en_HK
dc.identifier.scopusauthoridCheng, SWK=7404684779en_HK
dc.identifier.scopusauthoridWu, LLH=7404903103en_HK
dc.identifier.scopusauthoridCheung, GCY=15052803300en_HK

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats